204 related articles for article (PubMed ID: 32648245)
61. Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.
Carvalho JL; Silva-Carvalho AE; Garcez EM; Saldanha-Araujo F
Front Immunol; 2021; 12():682195. PubMed ID: 33995424
[No Abstract] [Full Text] [Related]
62. Ventilation support in SARS-CoV-2 pneumonia. Strategy and indication.
Gordo F; Parro K; Mohamed M
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):50-53. PubMed ID: 35488827
[TBL] [Abstract][Full Text] [Related]
63. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.
Lu J; Xie ZY; Zhu DH; Li LJ
World J Clin Cases; 2021 Mar; 9(7):1705-1713. PubMed ID: 33728315
[TBL] [Abstract][Full Text] [Related]
64. Weiss Response to Sengupta et al. (DOI: 10.1089/scd.2020.0095).
Weiss DJ; Lim SK; Rohde E; Witwer KW; Giebel B
Stem Cells Dev; 2020 Dec; 29(24):1533-1534. PubMed ID: 33301389
[No Abstract] [Full Text] [Related]
65. Use of mesenchymal stem cell therapy in COVID-19 related strokes.
Rawat M; Ng C; Khan E; Shah RA; Ashfaq S; Bahader GA; Shah ZA
Neural Regen Res; 2023 Sep; 18(9):1881-1883. PubMed ID: 36926703
[TBL] [Abstract][Full Text] [Related]
66. COVID-19: A master stroke of Nature.
Singh SK
AIMS Public Health; 2020; 7(2):393-402. PubMed ID: 32617365
[TBL] [Abstract][Full Text] [Related]
67. Targeting mesenchymal stem cell therapy for severe pneumonia patients.
Lam G; Zhou Y; Wang JX; Tsui YP
World J Stem Cells; 2021 Feb; 13(2):139-154. PubMed ID: 33708343
[TBL] [Abstract][Full Text] [Related]
68. Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?
Irmak DK; Darıcı H; Karaöz E
Aging Dis; 2020 Oct; 11(5):1174-1191. PubMed ID: 33014531
[TBL] [Abstract][Full Text] [Related]
69. Promising impacts of mesenchymal stem cell therapy in treatment of SARS-CoV-2 (COVID-19).
Khorshidi M; Zarezadeh M; Emami M; Olang B; Moradi Moghaddam O
Heart Lung; 2020; 49(6):745-748. PubMed ID: 32911459
[No Abstract] [Full Text] [Related]
70. Mesenchymal stem cells and COVID-19: the process of discovery and of translation.
Caplan AI
Biomater Transl; 2021; 2(4):307-311. PubMed ID: 35837414
[TBL] [Abstract][Full Text] [Related]
71. Expanded mesenchymal stem cells: a novel therapeutic approach for SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain.
Soler Rich R; Rius Tarruella J; Melgosa Camarero MT
Med Clin (Engl Ed); 2020 Oct; 155(7):318-319. PubMed ID: 32959021
[No Abstract] [Full Text] [Related]
72. Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19.
Hmadcha A; Soria B; Zhao RC; Smani T; Valverde I
Front Cell Dev Biol; 2021; 9():813384. PubMed ID: 34970555
[No Abstract] [Full Text] [Related]
73. Covid-19 cases around the world.
Fricker RD
Signif (Oxf); 2020 Dec; 17(6):4-5. PubMed ID: 33362873
[No Abstract] [Full Text] [Related]
74. Mesenchymal Stem Cell Transplantation for COVID-19 Treatment in a Puerperium Period in Intensive Care Unit.
Sahin AS; Kaya E; Turgut G; Dolay K; Kocatas A
Turk J Anaesthesiol Reanim; 2021 Oct; 49(5):428-429. PubMed ID: 35110048
[No Abstract] [Full Text] [Related]
75. Mesenchymal stem cells in the treatment of severe COVID-19.
Kesari S; Kasper GC; Verkh L; Hammond TC; Matal ML; Hammerling JW; Tankovich N; Lim AP; Zhao KH; Juarez T; Redfern RE; Gill JM; Nomura N; Hiemer A; Heng A; Shoemaker J
Transl Med Commun; 2021; 6(1):16. PubMed ID: 34395912
[No Abstract] [Full Text] [Related]
76. Can we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?
Şahin AS; Kaya E; Turgut G; Kocataş A
J Turk Ger Gynecol Assoc; 2021 May; 22(2):149-150. PubMed ID: 33663198
[No Abstract] [Full Text] [Related]
77. Drug-Resistant Yeast Infections Spread in COVID-19 Unit.
Kuehn BM
JAMA; 2021 Feb; 325(8):714. PubMed ID: 33620416
[No Abstract] [Full Text] [Related]
78. COVID-19 Expands Its Territories from Humans to Animals.
Gao GF; Wang L
China CDC Wkly; 2021 Oct; 3(41):855-858. PubMed ID: 34703641
[No Abstract] [Full Text] [Related]
79. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment.
Jayaramayya K; Mahalaxmi I; Subramaniam MD; Raj N; Dayem AA; Lim KM; Kim SJ; An JY; Lee Y; Choi Y; Raj A; Cho SG; Vellingiri B
BMB Rep; 2020 Aug; 53(8):400-412. PubMed ID: 32731913
[TBL] [Abstract][Full Text] [Related]
80. Mesenchymal stem cell research progress for the treatment of COVID-19.
Yao D; Ye H; Huo Z; Wu L; Wei S
J Int Med Res; 2020 Sep; 48(9):300060520955063. PubMed ID: 32972277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
